Olanzapine N-Oxide
Code | Size | Price |
---|
TAR-T28231-1mg | 1mg | £290.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28231-1mL | 1 mL * 10 mM (in DMSO) | £563.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28231-5mg | 5mg | £577.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28231-10mg | 10mg | £830.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28231-25mg | 25mg | £1,187.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28231-50mg | 50mg | £1,581.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28231-100mg | 100mg | £2,135.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Olanzapine N-oxide is a metabolite of Olanzapine, an antipsychotic medication used to treat bipolar and schizophrenia disorder.
CAS:
174794-02-6
Formula:
C17H20N4OS
Molecular Weight:
328.43
Purity:
0.98
SMILES:
Cc1cc2c(Nc3ccccc3N=C2N2CC[N+](C)([O-])CC2)s1
References
1. Okubo M, Narita M, Murayama N, Akimoto Y, Goto A, Yamazaki H. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. Hum Psychopharmacol. 2016 Mar;31(2):83-92. doi: 10.1002/hup.2515. Epub 2016 Feb 8. PubMed PMID: 26856397.
2. Johnson JT, Everly AG, Kpakima FE, Detke HC. Postmortem redistribution of olanzapine following intramuscular administration of olanzapine pamoate in dogs. Forensic Sci Int. 2015 Dec;257:353-8. doi: 10.1016/j.forsciint.2015.09.022. Epub 2015 Oct 22. PubMed PMID: 26517823.
3. Korprasertthaworn P, Polasek TM, Sorich MJ, McLachlan AJ, Miners JO, Tucker GT, Rowland A. In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism. Drug Metab Dispos. 2015 Nov;43(11):1806-14. doi: 10.1124/dmd.115.064790. Epub 2015 Sep 1. PubMed PMID: 26329789.
4. S?derberg MM, Dahl ML. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 2013 Aug;14(11):1319-36. doi: 10.2217/pgs.13.120. Review. PubMed PMID: 23930678.